ClinicalTrials.gg

Program

QY201

A development code. Also written as “QY201 Tablets(10mg)”, “QY201 Tablets(20mg)” and “QY201 Tablets(5mg)”.

Its studies are mostly in Dermatitis, Atopic · Vitiligo, led by E-nitiate Biopharmaceuticals (Hangzhou).

Furthest: phase 3, since Sep 10, 20254 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
E-nitiate Biopharmaceuticals (Hangzhou)43 open or runningphase 3since Sep 10, 2025Aug 28, 2022Dec 31, 2026phase 2 · NCT07712523

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 28, 2022First study: phase 2 study in Dermatitis, AtopicFirst studyNCT05525715 · 260 planned
  2. Sep 10, 2025Phase 3 study in Dermatitis, AtopicNCT07180511 · 460 planned · China
  3. Jul 14, 20262 phase 2 studiesNCT07712536, NCT07712523

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Adult Subjects With Non-Segmental VitiligoNCT07712523
  2. May 18, 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT07180511

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07712536Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD) · China2CompletedDec 19, 202524
NCT07712523Adult Subjects With Non-Segmental Vitiligo · China2RecruitingDec 31, 2026200
NCT07180511Dermatitis, Atopic · China3By invitationMay 18, 2027460
NCT05525715Dermatitis, Atopic2Not yet recruitingDec 2025260

How it is read

Names in the registry

  • “QY201 Tablets(10mg)”, 2 entries
  • “QY201 Tablets(20mg)”, 2 entries
  • “QY201 Tablets(5mg)”, 1 entry
  • “10mg QY201 tablet”, 1 entry
  • “20mg QY201 tablet”, 1 entry

Codes read as this program: QY201.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.